◼ Archived
Business
🔮 fades ✓
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi pays Regeneron $1B upfront for 4 early-stage assets to expand immunology alliance
Regeneron
5 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Regeneron
This hub groups 5 separate news trends connected to Regeneron, spanning June 29, 2026 through October 1, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 47 article observations and 45 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind
9 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Kodiak Sciences stock soars on positive AMD trial data
Investors cheer as Kodiak Sciences’ AMD trial lifts its stock double and adds $3 billion to market cap.
◼ Archived
Business
🔮 fades ✓
Regeneron backs $75M series A for antibody upstart Infinimmune
Alameda-based biotech Infinimmune has secured $75 million in Series A funding to advance its antibody pipeline for atopic dermatitis and inflammatory diseases.
◼ Archived
Business
🔮 fades ✓
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
The FDA is launching a pilot program to accelerate the review process for new pharmaceutical manufacturing facilities, starting with Eli Lilly and Regeneron.